secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0001815776-24-000053
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LENZ submits NDA for LNZ100 (aceclidine) to FDA for presbyopia treatment
------------------------------------------------------------------------

- NDA supported by Phase 3 CLARITY study: met all primary and secondary near vision endpoints.
- LNZ100 is an aceclidine-based eye drop targeting presbyopia, affecting ~1.8B people globally.
- No serious treatment-related adverse events observed over 30,000 study days.
- FDA has 60-day filing review period to determine NDA completeness for acceptance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000181577624000053/0001815776-24-000053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000181577624000053/lenz-20240812.htm
  HTML page:      https://secwatch.observer/filing/0001815776-24-000053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer